Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Sarcoma 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Mesothelioma 1Lung Neoplasms 1Liver Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × Cell- and Tissue-Based Therapy × Clear all
NCT06196294 2024-06-26

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Second Affiliated Hospital of Guangzhou Medical University

Phase 1 Recruiting
30 enrolled
GastrointestinalOther solid neoplasmThoracic

Liver Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡